Cancer Biother Radiopharm. 2002 Jun;17(3):317-26. Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin-like peptide. Varvarigou AD, Scopinaro F, Leondiadis L, Corleto V, Schillaci O, De Vincentis G, Sourlingas TG, Sekeri-Pataryas KE, Evangelatos GP, Leonti A, Xanthopoulos S, Delle Fave G, Archimandritis SC. SourceNational Center for Scientific Research Demokritos, Athens 153 10, Hellas, Greece. avar@mail.demokritos.gr Abstract A new pentadecapeptide bombesin analogue was prepared by Fmoc synthesis, purified by HPLC and identified by electron ionization mass spectrometry. The biological activity of the new peptide was tested on isolated human colonic muscle cells and compared to native bombesin. Labelling of the new biomolecule with Tc-99m yielded a single radioactive species which remained stable at room temperature for eight hours. In a binding assay, the radiolabelled peptide showed high affinity for oat-cell carcinoma (Kd = 9.8 nM) and colorectal adenocarcinoma (Kd = 27.2 nM). Biodistribution studies, performed in normal rodents, indicated uptake by organs that normally express bombesin receptors, such as liver, intestines and kidneys. Scintigraphic studies, performed in nude mice transplanted with small cell lung carcinoma and colon cancer cells, showed significant tumor uptake two hours p.i. The new synthetic pentadecapeptide appears to have promise for several malignancies, including oat-cell lung carcinoma, colorectal cancer and gastroenteropancreatic (GEP) tumors. PMID:12136524[PubMed - indexed for MEDLINE]

Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin-like peptide / Varvarigou, A. D.; Scopinaro, Francesco; Leondiadis, L.; Corleto, Vito Domenico; Schillaci, O.; DE VINCENTIS, Giuseppe; Sourlingas, T. G.; SEKERI PATARYAS, K. E.; Evangelatos, G. P.; Leonti, A; Xathopoulos, S.; DELLE FAVE, Gianfranco; Archimandritis, S. C.. - In: CANCER BIOTHERAPY & RADIOPHARMACEUTICALS. - ISSN 1084-9785. - 17:(2002), pp. 317-326. [10.1089/10849780260179288]

Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin-like peptide.

SCOPINARO, Francesco;CORLETO, Vito Domenico;DE VINCENTIS, Giuseppe;DELLE FAVE, Gianfranco;
2002

Abstract

Cancer Biother Radiopharm. 2002 Jun;17(3):317-26. Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin-like peptide. Varvarigou AD, Scopinaro F, Leondiadis L, Corleto V, Schillaci O, De Vincentis G, Sourlingas TG, Sekeri-Pataryas KE, Evangelatos GP, Leonti A, Xanthopoulos S, Delle Fave G, Archimandritis SC. SourceNational Center for Scientific Research Demokritos, Athens 153 10, Hellas, Greece. avar@mail.demokritos.gr Abstract A new pentadecapeptide bombesin analogue was prepared by Fmoc synthesis, purified by HPLC and identified by electron ionization mass spectrometry. The biological activity of the new peptide was tested on isolated human colonic muscle cells and compared to native bombesin. Labelling of the new biomolecule with Tc-99m yielded a single radioactive species which remained stable at room temperature for eight hours. In a binding assay, the radiolabelled peptide showed high affinity for oat-cell carcinoma (Kd = 9.8 nM) and colorectal adenocarcinoma (Kd = 27.2 nM). Biodistribution studies, performed in normal rodents, indicated uptake by organs that normally express bombesin receptors, such as liver, intestines and kidneys. Scintigraphic studies, performed in nude mice transplanted with small cell lung carcinoma and colon cancer cells, showed significant tumor uptake two hours p.i. The new synthetic pentadecapeptide appears to have promise for several malignancies, including oat-cell lung carcinoma, colorectal cancer and gastroenteropancreatic (GEP) tumors. PMID:12136524[PubMed - indexed for MEDLINE]
2002
bombesin
01 Pubblicazione su rivista::01a Articolo in rivista
Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin-like peptide / Varvarigou, A. D.; Scopinaro, Francesco; Leondiadis, L.; Corleto, Vito Domenico; Schillaci, O.; DE VINCENTIS, Giuseppe; Sourlingas, T. G.; SEKERI PATARYAS, K. E.; Evangelatos, G. P.; Leonti, A; Xathopoulos, S.; DELLE FAVE, Gianfranco; Archimandritis, S. C.. - In: CANCER BIOTHERAPY & RADIOPHARMACEUTICALS. - ISSN 1084-9785. - 17:(2002), pp. 317-326. [10.1089/10849780260179288]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/252716
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 34
social impact